Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summi...
June 17 2021 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company
dedicated to the development of cellular therapies designed to
reverse disease, today announced that David J. Mazzo, PhD,
President and Chief Executive Officer of Caladrius, will present at
the Investor Forum at the World Stem Cell Summit to be held
(virtually) June 14-18, 2021. The Company’s presentation will begin
today, June 17th at 10:30 a.m. Eastern time and consist of a
20-minute corporate overview and research update, followed by a
20-minute Q&A session moderated by a Noble Capital Markets
equity research representative.
The presentation can be accessed in two ways: by registering for
the full World Stem Cell
Summit www.worldstemcellsummit.com, or by completing the
free registration for the Investor Forum only
at www.channelchek.com. A replay of the presentation webcast
will be archived on Channelchek as part of its C-Suite Series,
available at www.channelchek.com/c-suite, and on its YouTube
channel, www.youtube.com/channelchek.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study (https://www.freedom-trial.com/) in
the U.S. for the treatment of coronary microvascular dysfunction
(“CMD”); HONEDRA® (CLBS12), recipient of orphan designation
for Buerger’s Disease in the U.S. as well as SAKIGAKE
designation and eligible for early conditional approval in Japan
for the treatment of critical limb ischemia (“CLI”) and Buerger’s
Disease based on the results of an ongoing clinical trial; CLBS201,
designed to assess the safety and efficacy of CD34+ cell therapy as
a treatment for diabetic kidney disease (“DKD”); and OLOGO™
(CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”)
designated therapy for which the Company is in discussion with the
FDA to finalize a Phase 3 protocol of reduced size and scope for a
confirmatory trial in subjects with no-option refractory disabling
angina (“NORDA”). For more information on the Company, please
visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John
MendittoVice President, Investor Relations and Corporate
CommunicationsPhone: +1-908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryKelly WakeleePhone:
610.639.2774Email: kwakelee@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024